Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call

Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference
                                     Call

PR Newswire

SAN DIEGO, Feb. 19, 2013

SAN DIEGO, Feb. 19, 2013 /PRNewswire/ --Halozyme Therapeutics, Inc. (NASDAQ:
HALO) will webcast its Quarterly Update Conference Call for the fourth quarter
and full year 2012 on Monday, February 25, 2013 at 4:30 p.m. ET/1:30 p.m. PT.
Gregory I. Frost, Ph.D., President and Chief Executive Officer, will lead the
call. On the same date pre-market, Halozyme will release financial results for
the fourth quarter and year-ended December 31, 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's
corporate website and a recording will be made available following the close
of the call. To access the webcast, please log on to www.halozyme.com
approximately fifteen minutes prior to the call to register, download and
install any necessary audio software. For those without access to the
Internet, the live call may be accessed by phone by calling (877) 407-8037
(domestic callers) or (201) 689-8037 (international callers). A telephone
replay will be available shortly after the call by dialing (877) 660-6853
(domestic callers) or (201) 612-7415 (international callers) using replay ID
number 409638.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing
and commercializing innovative products that advance patient care. With a
diversified portfolio of enzymes that target the extracellular matrix, the
Company's research focuses primarily on a family of human enzymes, known as
hyaluronidases, which increase the absorption and dispersion of biologics,
drugs and fluids. Halozyme's pipeline addresses therapeutic areas, such as
diabetes, oncology and dermatology that have significant unmet medical need.
The Company markets Hylenex® recombinant (hyaluronidase human injection) and
has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme
is headquartered in San Diego, CA. For more information on how we are
innovating, please visit our corporate website at www.halozyme.com.

Investor Contact:
Kurt Gustafson
Halozyme Therapeutics
858-704-8272
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
310-633-9434
Nurha.Hindi@hkstrategies.com

SOURCE Halozyme Therapeutics, Inc.

Website: http://www.halozyme.com